South African Vaccine Manufacturer Secures 1.8 Billion UAH Funding
South African vaccine manufacturer BioVac has secured a financing package of 1.8 billion UAH from the International Finance Corporation, the European Commission, and the European Investment Bank. The company will build Africa's first end-to-end multi-vaccine manufacturing site in Cape Town. This initiative aims to enhance self-reliance in vaccine production for Africa, addressing gaps identified during the COVID-19 pandemic.
Topics
Developing
- 862d Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore.
- 862d Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
- 862d Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est.
- 862d Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium.
Sources · 7 independent
SAfm
“The vaccine manufacturer BioVac is said to employ over 700 high-end skilled individuals. It has secured a financing package of 1.8 billion UAH from the International Finance Corporation, the European Commission, and the European Investment Bank.”
Unlock the full story
Get a Pro subscription or above to see the live story progression and the full list of independent sources confirming each event as they happen.
Log in to upgrade